New mRNA Drug REP-0004 Targets Liver to Rapidly Reverse Heart Disease and Atherosclerosis
Repair Biotechnologies' REP-0004 uses mRNA-lipid nanoparticles to clear toxic free cholesterol from the liver, reversing plaque and liver disease.
Summary
Repair Biotechnologies is developing REP-0004, an mRNA-based drug delivered via lipid nanoparticles directly to liver cells. It works by breaking down excess intracellular free cholesterol — a toxic buildup that worsens with age and obesity. By making the liver act as though it is cholesterol-deficient, the drug triggers the body to pull excess cholesterol from tissues throughout the body, creating a systemic clearing effect. Early results show rapid and dramatic regression of atherosclerotic plaque and reversal of liver disease including fibrosis. The FDA has granted orphan drug designation, and clinical trials are targeted for mid-2027. This approach could represent a meaningful advance in treating cardiovascular and metabolic disease driven by cholesterol accumulation.
Detailed Summary
Repair Biotechnologies is advancing REP-0004, a novel mRNA therapy designed to tackle one of the root drivers of cardiovascular disease and metabolic liver disease: excess intracellular free cholesterol. Unlike standard cholesterol-lowering drugs that work in the bloodstream, this approach targets the problem inside cells, where unmodified free cholesterol accumulates and becomes toxic, especially as we age or gain weight.
The drug is delivered intravenously using lipid nanoparticles sized to pass through blood vessel walls into the liver. A surface ligand ensures the particles bind exclusively to hepatocytes — liver cells — where the encapsulated mRNA is released and translated into proteins that selectively break down excess free cholesterol. Critically, this process does not affect cholesterol outside cells or in other organs directly.
Once free cholesterol is cleared in the liver, a powerful homeostatic feedback loop activates. The liver, sensing a cholesterol deficit, ramps up reverse cholesterol transport — actively pulling excess free cholesterol from tissues throughout the body back to the liver, where it is broken down. This systemic cascade produces rapid regression of atherosclerotic plaque and reversal of metabolic liver disease, including fibrosis, in preclinical models.
Notably, the problem of excess free cholesterol is not limited to obese individuals. Thin people can also accumulate toxic levels in their liver and other tissues, making this therapy potentially relevant to a broad aging population. The drug also addresses oxidized cholesterol forms like 7-ketocholesterol within cells, which are key components of dangerous soft plaques.
The FDA has granted Repair Biotechnologies an orphan drug designation, and the company is targeting clinical trials by mid-2027. While preclinical results are described as dramatic, human trial data is not yet available. Regulatory and manufacturing challenges remain, and independent peer-reviewed publication of the underlying data has not been cited in this interview.
Key Findings
- REP-0004 uses mRNA-lipid nanoparticles to selectively clear toxic free cholesterol inside liver cells
- Drug triggers systemic reverse cholesterol transport, removing excess cholesterol from tissues body-wide
- Preclinical results show rapid, dramatic atherosclerotic plaque regression and reversal of liver fibrosis
- Excess intracellular free cholesterol accumulates with both aging and obesity, affecting even lean individuals
- FDA orphan drug designation granted; human clinical trials targeted for mid-2027
Methodology
This is a founder interview published by Lifespan.io, a longevity-focused science media outlet. Evidence is based on the company's own preclinical findings as described by the CEO; no peer-reviewed publications or independent data are cited. The source has reasonable credibility in the longevity space but this represents company-reported findings, not independently validated research.
Study Limitations
All efficacy claims are preclinical and reported by the company itself; no peer-reviewed data is referenced. Human clinical trials have not yet begun, so safety and efficacy in humans remain unconfirmed. The article content was truncated, meaning some technical details or caveats from the original interview may be missing.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.